Besides, CHK absence or its promoter methylation in colon cancer and brain cancer suggests its potential as a molecular biomarker in these cancer types and holds promise to become a novel cancer diagnosis standard alone or in combination with other molecules based on further clinical investigations. This evidence concerns the gene MATK and cancer.